Cargando…

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females

As global supply is still inadequate to address the worldwide requirements for HPV vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine. In this randomized, double-blind, placebo-controlled, phase 2 trial, healthy 9–45-year-old Chinese females in three age cohorts (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Li-Wei, Li, Juan, Yu, Bang-Wei, Huang, Li-Rong, Li, Ke, Ji, Min, Zhou, Ling-Yun, Yuan, Lin, Yang, Shu-Yuan, Chen, Jing-Jing, Wang, Ling, Jiang, Zhi-Wei, Li, Rong-Cheng, Li, Yan-Ping, Xia, Jie-Lai, Mo, Zhao-Jun, Li, Chang-Gui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	HPV
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294733/ https://www.ncbi.nlm.nih.gov/pubmed/37249310 http://dx.doi.org/10.1080/21645515.2023.2209001

Ejemplares similares

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9–14-year-old and 18–26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial
por: Li, Juan, et al.
Publicado: (2023)

Long-Term immunopersistence and safety of the Escherichia coli-produced HPV-16/18 bivalent vaccine in Chinese adolescent girls
por: Yao, Xingmei, et al.
Publicado: (2022)

A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation
por: Ishimoto, Tatsuki, et al.
Publicado: (2023)

Perceptions and acceptability of HPV vaccination among parents of female adolescents 9–14 in China: A cross-sectional survey based on the theory of planned behavior
por: Yi, Youqin, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Knowledge of HPV, its vaccines, and attitudes toward HPV vaccines among obstetrician-gynecologists, pediatricians and immunization services providers in Western China
por: Ma, Jianqiao, et al.
Publicado: (2021)

Multiple infections containing the top five prevalent HPV genotypes and their impact on cervical lesions in Changzhou, China
por: Gong, Ping, et al.
Publicado: (2023)

AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION
por: Carestiato, Fernanda Nahoum, et al.
Publicado: (2013)

The influence of political ideology on awareness of HPV and HPV vaccine among adults in the United States
por: Chido-Amajuoyi, Onyema Greg, et al.
Publicado: (2023)

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
por: Mo, Zhao-Jun, et al.
Publicado: (2022)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge
por: Hoes, J., et al.
Publicado: (2021)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

Social and psychological impact of HPV testing in cervical screening: a qualitative study
por: McCaffery, K, et al.
Publicado: (2006)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China
por: Wu, Huamei, et al.
Publicado: (2023)

HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic
por: Ma, Yongmei, et al.
Publicado: (2023)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

Parents’ stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors
por: McKenzie, Ashley Hedrick, et al.
Publicado: (2023)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Individual, systemic and state factors associated with provider recommendation of HPV vaccination: Findings from NIS-Teen, 2020
por: Osaghae, Ikponmwosa, et al.
Publicado: (2023)

Multilevel perspectives on school-based opportunities to improve HPV vaccination among medically underserved adolescents: Beyond school entry mandates
por: Shin, Michelle B., et al.
Publicado: (2023)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China
por: Yuan, Haowen, et al.
Publicado: (2023)

Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics
por: Zorn, Sherri, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ars16vv4unhi0illi7lv0826vm